Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus-Reference-Cited by-同舟云学术

Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus

Published:2021-04-02 Issue:5 Volume:5 Page:736-748
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatol Commun

Author:

Zhang Enxiang¹²³,Zhao Yang⁴⁵,Hu Hongbo²

Affiliation:

1. Key Laboratory of Growth Regulation and Transformation Research of Zhejiang Province School of Life Sciences Westlake Institute for Advanced StudyWestlake University Shilongshan Hangzhou China

2. Beijing Advanced Innovation Center for Food Nutrition and Human Health College of Food Science and Nutritional Engineering China Agricultural University Beijing China

3. Department of Biochemistry, Molecular Biology, and Biophysics University of Minnesota Minneapolis MN

4. Department of Cardiology Zhejiang Provincial People’s Hospital Hangzhou China

5. Cardiovascular Division Department of Medicine University of Minnesota Minneapolis MN

Funder

National Natural Science Foundation of China

China Scholarship Council

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.1611

Reference106 articles.

1. Diagnosis and Classification of Diabetes Mellitus

2. Diabetic nephropathy – complications and treatment

3. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research

4. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

5. Central Diabetes Insipidus: Clinical Characteristics and Long-Term Course in a Large Cohort of Adults

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the potential impact of sodium–glucose cotransporter‐2 inhibitor “canagliflozin” on the hepatic damage triggered by hypertension in rats;Microscopy Research and Technique;2024-07-25

2. Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis;Diabetes, Metabolic Syndrome and Obesity;2024-02

3. Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis;Diabetes, Obesity and Metabolism;2023-12-12

4. Unfolded Protein Response Signaling in Liver Disorders: A 2023 Updated Review;International Journal of Molecular Sciences;2023-09-14

5. Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study;Diabetes, Metabolic Syndrome and Obesity;2023-09